Research and Markets has announced the addition of the "Global Gastrointestinal Therapeutics Market 2016-2020" report to their offering.
The global gastrointestinal therapeutics market to grow at a CAGR of 6.5% during the period 2016-2020.
The report covers the present scenario and the growth prospects of the global gastrointestinal therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of various gastrointestinal disorders including IBD, and irritable bowel syndrome (IBS).
According to the report, increasing consumption of biologics will be a key driver for market growth. Biologics, available as either intravenous or subcutaneous injections, are increasingly becoming the treatment of choice for IBD. These therapeutics act by either blocking the interleukins or the TNF-a. HUMIRA (adalimumab), Remicade (infliximab), Simponi (golimumab), and Cimzia (Certolizumab pegol) are some anti-TNF agents, and Tysabri (natalizumab) and ENTYVIO (vedolizumab) are some anti-integrin agents available in the market for the treatment of ulcerative colitis and Crohn's disease. Apart from the already approved drugs, many biologics are still under development for the treatment of IBD.
Gastrointestinal disorders include both functional and motility disorders affecting the gastrointestinal tract. Functional disorders involve an abnormality in the working of the gastrointestinal tract. They are the most common type of disorders and present with disturbances in motility, visceral hypersensitivity, changes in the mucosal and immune function, variations in central nervous system processing, and altered gut microbiota.
Motility disorders are characterized by changes in the movement of the gastrointestinal tract and the transfer of its contents. Some of the most common gastrointestinal functional and motility disorders include IBS, GERD, Crohn's disease, ulcerative colitis, and peptic ulcers.
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Market research methodology
Part 04: Introduction
Part 05: Pipeline portfolio
Part 06: Market landscape
Part 07: Market segmentation by disease type
Part 08: Global IBD therapeutics market
Part 09: Global IBS therapeutics market
Part 10: Global gastrointestinal OTC drugs market
Part 11: Geographical segmentation
Part 12: Market drivers
Part 13: Impact of drivers
Part 14: Market challenges
Part 15: Impact of drivers and challenges
Part 16: Market trends
Part 17: Vendor landscape
Part 18: Key vendor analysis
For more information about this report visit http://www.researchandmarkets.com/research/38l3vm/global.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161107005908/en/Business Wire
Last updated on: 07/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.